Is Shree Pacetronix overvalued or undervalued?

As of 13 November 2025, the valuation grade for Shree Pacetronix has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued, with a PE ratio of 42.72, an EV to EBITDA ratio of 23.96, and a ROCE of 18.04%. These metrics suggest that the company is positioned favorably compared to its peers.
In comparison to its industry peers, Shree Pacetronix's PE ratio is significantly lower than that of Poly Medicure, which stands at 55.2, and Vimta Labs at 46.78, both categorized as very expensive. Additionally, the PEG ratio of Shree Pacetronix at 11.91 further supports its attractive valuation relative to peers like Blue Jet Health, which has a PEG of 0.28. Notably, Shree Pacetronix has outperformed the Sensex with a year-to-date return of 119.32% compared to the Sensex's 8.11%, reinforcing its strong market position.